Yahoo Finance7d
Amgen profits rise, next MariTide studies start by mid-year
(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...
pharmaphorum4d
Amgen's big reveal of obesity data falls a little flat
Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...
Business Insider7d
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Additionally, Amgen stated: “MariTide is a differentiated peptide-antibody conjugate that activates the glucagon like peptide 1 receptor and antagonizes gastric inhibitory polypeptide receptor.
Reuters8d
Amgen profits rise, next MariTide studies start by mid-year
MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...
Yahoo Finance7d
Amgen profits rise, next MariTide studies start by mid-year
(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...